Rigel Pharmaceuticals RIGL

NAS: RIGL | ISIN: US7665596034   26/04/2024
1,100 USD (0,00%)
(0,00%)   26/04/2024

10 april 2024 · Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

4 april 2024 · Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma · Persbericht

12 maart 2024 · Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer · Persbericht

5 maart 2024 · Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

27 februari 2024 · Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update · Persbericht

22 februari 2024 · Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® · Persbericht

8 januari 2024 · Rigel Pharmaceuticals Provides Business Update · Persbericht

5 januari 2024 · Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

4 januari 2024 · Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma · Persbericht

3 januari 2024 · Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

8 december 2023 · Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers · Persbericht

7 november 2023 · Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update · Persbericht

6 november 2023 · Rigel to Present at the Jefferies London Healthcare Conference · Persbericht

2 november 2023 · Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition · Persbericht

31 oktober 2023 · Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update · Persbericht

11 oktober 2023 · Rigel Announces Presentation at the Upcoming IDWeek 2023 · Persbericht

6 oktober 2023 · Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

20 september 2023 · Rigel to Present at the 2023 Cantor Global Healthcare Conference · Persbericht

30 augustus 2023 · Rigel to Participate in Upcoming September Investor Conferences · Persbericht

1 augustus 2023 · Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update · Persbericht

Mijn selecties